acute myeloid leukemia (AML)
Conditions
Interventions
No grouping:Bone marrow and oral mucosa cells
Sponsors
Institute of Hematology and Oncology of Harbin First Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Newly diagnosed AML patient with negative fusion genes and positive mutant genes (excluding APL); 2. Aged 18 to 65 years old, male or female; 3. And the normal function of liver and kidney: blood bilirubin: less than or equal to 35 mu; mol/L, AST/ALT,below the normal value limit of 2 times, less than or equal to 150 mu mol/L; 4. cardiac function is normal; 5. Performance status 0-3 (WHO standard); 6. Obtain informed consent signed by the patient or his family members.
Exclusion criteria
Exclusion criteria: 1. non newly diagnosed AML patients; 2. newly diagnosed AML patient with positive fusion genes; 3. newly diagnosed AML patient with negative mutant genes; 4. identify patients with central nervous system invasion; 5. Abnormal liver and kidney function, standard of over access group patients; 6. serious heart disease including myocardial infarction and cardiac insufficiency; 7. ECG results: QT interval is greater than 450 ms; 8. suffering from other malignant tumors of the viscera; 9. patientstive with active TB and HIV positive; 10. inability to understand or comply with research programmes; 11. Pregnant or lactating women; 12. There is drug addiction or mental illness; 13. participated in other clinical studies during the same period; 14. there are other conditions that hinder research; 15. patients who are ready for transplantation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Variable Allele Frequency(VAF) of Mutant Gene;Minimal Residual Disease; | — |
Countries
China
Contacts
Public ContactMa Jun
Institute of Hematology and Oncology of Harbin First Hospital
Outcome results
None listed